Financial Performance - The company achieved operating revenue of 80,372.89 million yuan in 2024, representing a year-on-year growth of 5.75% [2] - The net profit attributable to shareholders was 10,642.93 million yuan, a decrease of 21.01% year-on-year [2] - The net profit excluding non-recurring gains and losses was 8,347.32 million yuan, down 26.88% year-on-year, primarily due to increased operational costs from hiring new personnel [2] - The total cash dividend for 2024 was 1,987.65 million yuan, accounting for 18.68% of the annual net profit [4] Contractual and Project Engagement - The company signed new non-tax contracts worth 10 billion yuan in 2024, with a 33% increase in the second half compared to the first half [3] - As of the end of 2024, the total amount of existing non-tax contracts was 18.89 billion yuan, a year-on-year increase of 0.38% [2] - The company executed 2,161 SMO projects by the end of 2024, contributing to the launch of nearly 190 products domestically and internationally [2] Industry Position and Competitive Landscape - The SMO industry is entering a new development phase, with leading companies expanding client resources and talent scale, while smaller firms are gradually exiting the market [2] - The company collaborates with all of the top 10 global pharmaceutical companies, providing high-quality clinical trial management services [3] Future Outlook and Strategic Plans - The company plans to continue exploring innovations in organizational management and the application of AI and new technologies in clinical trial execution [2] - There are ongoing discussions regarding potential mergers and acquisitions, with a cautious approach to align with the company's long-term vision of becoming a data-driven clinical research service provider [4] - The actual controller and chairman plans to increase shareholding between 6 million to 9 million yuan from January 15 to July 14, 2025, reflecting confidence in the company's future [4]
普蕊斯(301257) - 301257普蕊斯调研活动信息20250512